Physician profile
Hani Rashid
NPI 1265842389
$12,594.01
in general payments reported to CMS, 2019-2025
30 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $152 · 2021: $3,214 · 2022: $3,539 · 2023: $3,368 · 2024: $2,042 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,510 · Education: $56.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,509.85 |
| Education | $56.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,966.69 | 2020-2024 | |
| Amgen INC. | $2,273.61 | 2021-2024 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,186.88 | 2021-2024 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,162.43 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,100.75 | 2021-2025 | |
| Lilly USA, LLC | $763.67 | 2021-2025 | Taltz |
| Glaxosmithkline, LLC. | $667.97 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $458.27 | 2021-2024 | |
| Horizon Therapeutics Plc | $429.96 | 2021-2023 | Krystexxa |
| Radius Health, INC. | $176.94 | 2022-2024 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $168.18 | 2021-2024 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.43 | 2022-2024 | Cyltezo, Ofev |
| Genentech USA, INC. | $132.98 | 2021-2023 | Actemra, Rituxan |
| Mallinckrodt Hospital Products INC. | $116.40 | 2022-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $116.21 | 2021-2024 | Orencia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $115.78 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $112.49 | 2021-2024 | Strensiq, Ultomiris |
| Fresenius Kabi USA, LLC | $88.19 | 2023-2024 | Idacio |
| Ani Pharmaceuticals, INC. | $68.45 | 2022-2024 | Purified Cortrophin Gel |
| Sandoz INC. | $57.55 | 2023 | Hyrimoz |
| Celltrion USA INC. | $41.05 | 2023 | Yuflyma |
| Aurinia Pharma U.S., INC. | $39.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $31.34 | 2023 | Truxima |
| Ferring Pharmaceuticals INC. | $29.32 | 2023-2024 | Euflexxa |
| Actelion Pharmaceuticals US, INC. | $28.94 | 2023 | Opsumit |
| Kyowa Kirin, INC. | $28.37 | 2024 | Crysvita |
| Zimmer Biomet Holdings, INC. | $26.61 | 2023 | Allograft |
| Bio Products Laboratory USA, INC. | $22.03 | 2022 | |
| Janssen Scientific Affairs, LLC | $20.34 | 2024 | Tremfya |
| Hikma Pharmaceuticals USA | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Rashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.